人参皂苷RG3通过PI3K/AKT/mTOR信号通路抑制胆囊癌细胞上皮间质转化

doi:10.16139/j.1007-9610.2026.01.12

摘要/Abstract

摘要：

目的：探索人参皂苷RG3抑制胆囊癌细胞的具体机制。方法：应用细胞计数试剂盒-8（CCK-8）实验，验证人参皂苷RG3对胆囊癌细胞活性的影响。通过细胞划痕实验和Transwell实验验证其对胆囊癌细胞迁移和侵袭的影响。通过蛋白质印迹实验验证其对上皮间质转化（EMT）相关蛋白质以及磷脂酰肌醇-3-激酶/蛋白激酶B/哺乳动物雷帕霉素靶蛋白[PI3K/PKB（AKT）/mTOR]信号通路相关蛋白质的影响。结果：人参皂苷RG3显著抑制胆囊癌细胞的活性，抑制细胞迁移的速率和Transwell实验中穿过小室的细胞数目。蛋白质印迹实验表明人参皂苷RG3显著降低磷酸化PI3K/AKT/mTOR蛋白的水平，上调E-钙黏着蛋白的表达水平，抑制N-钙黏着蛋白和波形蛋白的表达水平，最终抑制胆囊癌细胞EMT进程。结论：人参皂苷RG3抑制胆囊癌细胞活性，还通过调控PI3K/AKT/mTOR信号通路抑制胆囊癌细胞的EMT进程，抑制胆囊癌细胞迁移和侵袭。

关键词: 胆囊癌, 信号通路, 上皮间质转化, 人参皂苷RG3

Abstract:

Objective To explore the specific mechanism of Ginsenoside Rg3 inhibiting gallbladder cancer (GBC)cells. Methods Cell counting kit-8(CCK-8) assay was used to examine the effect of Ginsenoside Rg3 on the viability of GBC cells. The effect of Ginsenoside Rg3 on the migration and invasion of gallbladder cancer cells was verified by cell scratch assay and Transwell assay. Western blot was used to verify the effect of Ginsenoside Rg3 on epithelial-mesenchymal transition (EMT)-related proteins and phosphatidylinositol 3-kinase / protein kinase B (AKT) / mammalian target of rapamycin [PI3K/PKB(AKT)/mTOR] signaling pathway-related proteins. Results Ginsenoside Rg3 significantly inhibited the viability of GBC cells. Ginsenoside Rg3 significantly inhibited the rate of cell migration and the number of cells passing through the Transwell assay. Western blot showed that Ginsenoside Rg3 could significantly reduce the level of phosphorylated PI3K/AKT/mTOR protein, increase the expression level of E-cadherin, and inhibit the expression levels of N-cadherin and vimentin in gallbladder cancer cells, and finally inhibit the EMT process. Conclusions Ginsenoside RG3 inhibits the activity of gallbladder cancer cells, also suppresses the EMT process by regulating the PI3K/AKT/mTOR signaling pathway and inhibits the migration and invasion of gallbladder cancer cells.

Key words: Gallbladder cancer, Signaling pathway, Epithelial-mesenchymal transition(EMT), Ginsenoside Rg3

中图分类号:

R735.8

周忻, 王路兵, 章波. 人参皂苷RG3通过PI3K/AKT/mTOR信号通路抑制胆囊癌细胞上皮间质转化[J]. 外科理论与实践, 2026, 31(01): 70-76.

ZHOU Xin, WANG Lubing, ZHANG Bo. Ginsenoside RG3 inhibits epithelial-mesenchymal transition of gallbladder cancer cells through PI3K/AKT/mTOR signaling pathway[J]. Journal of Surgery Concepts & Practice, 2026, 31(01): 70-76.

图/表 5

图1

表1

图2

图3

图4

参考文献 20

[1]	CHEE M, WU A, FONG K Y, et al. Robotic, laparoscopic and open surgery for gallbladder cancer: a systematic review and network meta-analysis[J]. Surg Endosc, 2024, 38(9):4846-4857. doi: 10.1007/s00464-024-11162-6 pmid: 39148006
[2]	HE H, CHEN S, YU Y, et al. Comprehensive single-cell analysis deciphered microenvironmental dynamics and immune regulator olfactomedin 4 in pathogenesis of gallbladder cancer[J]. Gut, 2024, 73(9):1529-1542. doi: 10.1136/gutjnl-2023-331773 pmid: 38719336
[3]	ZHANG R, LI L, LI H, et al. Ginsenoside 20(S)-Rg3 reduces KIF20A expression and promotes CDC25A proteasomal degradation in epithelial ovarian cancer[J]. J Ginseng Res, 2024, 48(1):40-51. doi: 10.1016/j.jgr.2023.06.008 URL
[4]	WU L, BAI L, DAI W, et al. Ginsenoside Rg3: a review of its anticancer mechanisms and potential therapeutic applications[J]. Curr Top Med Chem, 2024, 24(10):869-884. doi: 10.2174/0115680266283661240226052054 pmid: 38441023
[5]	ZENG X, LIU S, YANG H, et al. Synergistic anti-tumour activity of ginsenoside Rg3 and doxorubicin on proliferation, metastasis and angiogenesis in osteosarcoma by modulating mTOR/HIF-1alpha/VEGF and EMT signalling pathways[J]. J Pharm Pharmacol, 2023, 75(11):1405-1417. doi: 10.1093/jpp/rgad070 URL
[6]	张英, 王学谦, 刘浩, 等. 参一胶囊联合化疗改善晚期非小细胞肺癌患者预后的多中心大样本随机临床研究[J]. 中华肿瘤杂志, 2018, 40(4):295-299.
	ZHANG Y, WANG X Q, LIU H, et al. A multicenter, large-sample, randomized clinical trial on improving the median survival time of advanced non-small cell lung cancer by combination of Ginseng Rg3 and chemotherapy[J]. Chin J Oncol, 2018, 40(4):295-299.
[7]	LEE Y, PARK A, PARK Y J, et al. Ginsenoside 20(R)-Rg3 enhances natural killer cell activity by increasing activating receptor expression through the MAPK/ERK signaling pathway[J]. Int Immunopharmacol, 2022, 107:108618. doi: 10.1016/j.intimp.2022.108618 URL
[8]	WANG X, HE R, GENG L, et al. Ginsenoside Rg3 alleviates cisplatin resistance of gastric cancer cells through inhibiting SOX2 and the PI3K/Akt/mTOR signaling axis by up-regulating miR-429[J]. Front Genet, 2022, 13:823182. doi: 10.3389/fgene.2022.823182 URL
[9]	ZHOU B, YAN Z, LIU R, et al. Prospective study of transcatheter arterial chemoembolization (TACE) with ginsenoside Rg3 versus TACE alone for the treatment of patients with advanced hepatocellular carcinoma[J]. Radiology, 2016, 280(2):630-639. doi: 10.1148/radiol.2016150719 URL
[10]	MANFIOLETTI G, FEDELE M. Epithelial-mesenchymal transition (EMT)[J]. Int J Mol Sci, 2023, 24(14):11386. doi: 10.3390/ijms241411386 URL
[11]	EBRAHIMI N, HAKIMZADEH A, BOZORGMAND F, et al. Role of non-coding RNAs as new therapeutic targets in regulating the EMT and apoptosis in metastatic gastric and colorectal cancers[J]. Cell Cycle, 2023, 22(20):2302-2323. doi: 10.1080/15384101.2023.2286804 URL
[12]	ROUPAKIA E, CHAVDOULA E, KARPATHIOU G, et al. Canonical NF-kappaB promotes lung epithelial cell tumour growth by downregulating the metastasis suppressor CD82 and enhancing epithelial-to-mesenchymal cell transition[J]. Cancers (Basel), 2021, 13(17):4302. doi: 10.3390/cancers13174302 URL
[13]	TU M, YIN X, ZHUANG W, et al. NSG1 promotes glycolytic metabolism to enhance esophageal squamous cell carcinoma EMT process by upregulating TGF-beta[J]. Cell Death Discov, 2023, 9(1):391. doi: 10.1038/s41420-023-01694-6
[14]	CHEN E X, HU S C, XU J Q, et al. Suppression of GATA3 promotes epithelial-mesenchymal transition and simultaneous cellular senescence in human extravillous trophoblasts[J]. Biochim Biophys Acta Mol Cell Res, 2024, 1871(7):119768. doi: 10.1016/j.bbamcr.2024.119768 URL
[15]	MAO X, JIN Y, FENG T, et al. Ginsenoside Rg3 inhibits the growth of osteosarcoma and attenuates metastasis through the Wnt/Beta-Catenin and EMT signaling pathway[J]. Evid Based Complement Alternat Med, 2020, 2020:6065124. doi: 10.1155/ecam.v2020.1 URL
[16]	WANG S, CHENG Z, CUI Y, et al. PTPRH promotes the progression of non-small cell lung cancer via glycolysis mediated by the PI3K/AKT/mTOR signaling pathway[J]. J Transl Med, 2023, 21(1):819. doi: 10.1186/s12967-023-04703-5
[17]	PANNEERPANDIAN P, GANESAN K. PI3K/AKT/mTOR inhibitors as potential extracellular matrix modulators for targeting EMT subtype gastric tumors[J]. Med Oncol, 2023, 40(4):120. doi: 10.1007/s12032-023-01984-0 pmid: 36934368
[18]	ANG H L, MOHAN C D, SHANMUGAM M K, et al. Mechanism of epithelial-mesenchymal transition in cancer and its regulation by natural compounds[J]. Med Res Rev, 2023, 43(4):1141-1200. doi: 10.1002/med.v43.4 URL
[19]	HU J, LI G, LIU Z, et al. Bicarbonate transporter SLC4A7 promotes EMT and metastasis of HNSCC by activating the PI3K/AKT/mTOR signaling pathway[J]. Mol Carcinog, 2023, 62(5):628-640. doi: 10.1002/mc.v62.5 URL
[20]	LUO M, CHEN Y J, XIE Y, et al. Dickkopf-related protein 1/cytoskeleton-associated protein 4 signaling activation by Helicobacter pylori-induced activator protein-1 promotes gastric tumorigenesis via the PI3K/AKT/mTOR pathway[J]. World J Gastroenterol, 2022, 28(47):6769-6787. doi: 10.3748/wjg.v28.i47.6769 URL

Cell line	Time	Concentration (µM)	Cell viability (%)
GBC-SD	24 h	0	100
		50	79.25±2.09^**
		100	62.31±2.53^****
		150	39.34±2.11^****
		200	20.07±2.55^****
	48 h	0	100
		50	69.03±7.55^****
		100	52.66±3.22^****
		150	41.66±2.00^****
		200	11.61±3.06^****
NOZ	24 h	0	100
		50	77.32±1.53^***
		100	62.33±2.51^***
		150	41.03±2.01^****
		200	20.29±1.51^****
	48 h	0	100
		50	67.00±3.02^***
		100	51.02±1.07^****
		150	27.33±2.09^****
		200	8.35±2.59^***